DEMONSTRATED SAFETY PROFILE IN MORE THAN 3,000 PATIENTS ACROSS 4 CLINICAL TRIALS"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1

Subjects in United States/Poland trial (10 through 25 years of age) with adverse events"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1,*
  DOSE 1: DOSE 2:
  BEXSERO
(N=110-114)
SALINE PLACEBO
(N=94-96)
BEXSERO
(N=107-109)
MENVEO
(N=90-92)
Local Adverse Reactions
Pain - Any (Severe) 90% (20%) 27% (2%) 83% (29%) 43% (8%)
Erythema: Any (≥1 mm) 50% 13% 45% 26%
>100 mm 0% 0% 0% 2%
Induration: Any (≥1 mm) 32% 10% 28% 23%
>100 mm 0% 0% 0% 2%
Systemic Adverse Reactions Any (Severe) Any (Severe)
Fatigue 37% (4%) 22% (0%) 35% (6%) 20% (2%)
Nausea 19% (4%) 4% (0%) 18% (4%) 4% (0%)
Myalgia 49% (12%) 26% (1%) 48% (13%) 25% (4%)
Arthralgia 13% (2%) 4% (0%) 16% (2%) 4% (0%)
Headache 33% (4%) 20% (1%) 34% (6%) 23% (3%)
Fever (≥38°C) 1% 1% 5% 0%
  Severe=unable to perform normal daily activity.
* The United States/Poland trial was a randomized, controlled study. 120 participants 10 through 25 years of age received at least 1 dose of BEXSERO, including 112 participants who received 2 doses of BEXSERO 2 months apart. 97 participants received saline placebo followed by MENVEO (Meningococcal [Groups A, C, Y, and W-135] Oligosaccharide Diphtheria CRM197 Conjugate Vaccine)."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1
Administered 2 months after dose 1.

Solicited events in 3 other clinical trials were comparable to the US/Poland trial, with the exception of severe myalgia (3%-7%) and severe pain in the United Kingdom trial (8%)."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1

Additional prelicensure safety experience"scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1

In a prelicensure agreement with the Centers for Disease Control and Prevention (CDC), serious adverse events were collected at 2 universities in 15,351 subjects who received at least 1 dose of BEXSERO for a period of 30 days after each dose. Serious adverse events were reported in 50 individuals (0.3%), including 1 case of anaphylaxis 30 minutes after vaccination."scrollbars=yes, resizable=yes, width=400, height=400,top=500, left=500"1

INDICATION

BEXSERO is a vaccine indicated for active immunization to prevent invasive disease caused by Neisseria meningitidis serogroup B. BEXSERO is approved for use in individuals 10 through 25 years of age.

Approval of BEXSERO is based on demonstration of immune response, as measured by serum bactericidal activity against three serogroup B strains representative of prevalent strains in the United States. The effectiveness of BEXSERO against diverse serogroup B strains has not been confirmed.

IMPORTANT SAFETY INFORMATION FOR BEXSERO

  • BEXSERO is contraindicated in cases of hypersensitivity, including severe allergic reaction, to any component of the vaccine, or after a previous dose of BEXSERO
  • Appropriate observation and medical treatment should always be readily available in case of an anaphylactic event following the administration of the vaccine
  • The tip caps of the prefilled syringes contain natural rubber latex, which may cause allergic reactions in latex-sensitive individuals
  • Syncope (fainting) can occur in association with administration of BEXSERO. Ensure procedures are in place to avoid injury from falling associated with syncope
  • The most common solicited adverse reactions observed in clinical trials were pain at the injection site (≥83%), myalgia (≥48%), erythema (≥45%), fatigue (≥35%), headache (≥33%), induration (≥28%), nausea (≥18%), and arthralgia (≥13%)
  • Vaccination with BEXSERO may not provide protection against all meningococcal serogroup B strains
  • Vaccination with BEXSERO may not result in protection in all vaccine recipients

Please see full Prescribing Information for BEXSERO.